SCHEMBL4474162

SCHEMBL4474162

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)c(Cl)c3)ccnc2cc1OCCCN1CC(C)OC(C)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.57
FLT1 P17948 14/20 0.55
FLT4 P35916 14/20 0.55
RIPK2 O43353 1/20 0.52
STK10 O94804 1/20 0.52
ABL1 P00519 1/20 0.52
LCK P06239 1/20 0.52
LYN P07948 1/20 0.52
RET P07949 1/20 0.52
MET P08581 1/20 0.52
PDGFRB P09619 1/20 0.52
KIT P10721 1/20 0.52
BCR P11274 1/20 0.52
FGFR1 P11362 1/20 0.52
SRC P12931 1/20 0.52
PDGFRA P16234 1/20 0.52
MAPK3 P27361 1/20 0.52
HTR2A P28223 1/20 0.52
MAPK1 P28482 1/20 0.52
EPHA2 P29317 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482169 0.98 KDR (0.55) KDRFLT1FLT4RIPK2STK10
SCHEMBL4466513 0.97 KDR (0.53) KDRFLT1FLT4RIPK2STK10
SCHEMBL13936761 0.97 KDR (0.53) KDRFLT1FLT4RIPK2STK10
SCHEMBL4469175 0.92 KDR (0.55) KDRFLT1FLT4RETMET
SCHEMBL4475333 0.90 KDR (0.59) KDRFLT1FLT4MET
SCHEMBL4465217 0.90 PDGFRA (0.59) KDRMETPDGFRA
SCHEMBL4479909 0.90 KDR (0.68) KDRFLT1FLT4
SCHEMBL13936829 0.90 PDGFRA (0.59) KDRMETPDGFRA
SCHEMBL4471382 0.89 KDR (0.63) KDRFLT1FLT4MET
SCHEMBL4477592 0.89 KDR (0.61) KDRFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 KDR 211/4885FLT1 115/4885FLT4 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.